Conditions: Post Menopausal Osteoporosis
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 356
Healthy volunteers: no

Brief summary:
This 2 arm crossover study will evaluate patient reported preference for either once monthly Boniva (150mg p.o.) or once weekly risedronate (35mg p.o.). Patients with post-menopausal osteoporosis will be randomized to receive Boniva for 3 calendar months or risedronate for 12 weeks; they will then cross over to receive the alternative treatment for a further 12 weeks/3 months. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Risedronate intervention 2: ibandronate [Bonviva/Boniva]
Intervention descriptions: intervention 1: 35mg po weekly for 12 weeks intervention 2: 150mg po monthly for 3 months

Protocol document: